Vaccines and other adjuvant therapies for melanoma Journal Article

  


Authors: Wolchok, J. D.; Livingston, P. O.; Houghton, A. N.
Article Title: Vaccines and other adjuvant therapies for melanoma
Abstract: Patients with thick primary melanomas or regional lymph node involvement are at high risk of relapse. Investigations of adjuvant therapy over the past 30 years show only one significantly positive trial employing high dose interferon-alpha-2b. This is a potentially toxic regimen, therefore, other better-tolerated forms of adjuvant immunotherapy are being studied. Recent advances in basic science have led to a better understanding of the T-cell response to human cancer. This article discusses the background and current clinical trials of active specific immunotherapies for melanoma, including peptide and ganglioside vaccines.
Keywords: cancer survival; clinical trial; review; fluorouracil; alpha interferon; adjuvant therapy; combined modality therapy; lymph node metastasis; alpha2b interferon; bcg vaccine; dacarbazine; interleukin 2; unindexed drug; melanoma; skin neoplasms; antineoplastic combined chemotherapy protocols; relapse; cyclophosphamide; melphalan; peptide; monoclonal antibody; tumor necrosis factor alpha; genetic transfection; immunotherapy; gamma interferon; cancer vaccines; adjuvant chemotherapy; antibody response; dna vaccine; tumor vaccine; antigen presenting cell; ganglioside gm2; vaccine; carbohydrate; b7 antigen; keyhole limpet hemocyanin; plasmid dna; immunization; intradermal drug administration; intramuscular drug administration; qs 21; ganglioside; delayed hypersensitivity; saponin; levamisole; heat shock protein; limb perfusion; corynebacterium parvum vaccine; virus oncolysate; vaccinia oncolysate; humans; human; priority journal; transfer factor
Journal Title: Hematology/Oncology Clinics of North America
Volume: 12
Issue: 4
ISSN: 0889-8588
Publisher: Elsevier Inc.  
Date Published: 1998-08-01
Start Page: 835
End Page: 848
Language: English
DOI: 10.1016/s0889-8588(05)70026-5
PUBMED: 9759582
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031706604&doi=10.1016%2fS0889-8588%2805%2970026-5&partnerID=40&md5=22dcf125a63b3ea0d0077e378422f2cf
Notes: Review -- Export Date: 12 December 2016 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Jedd D Wolchok
    905 Wolchok
  2. Philip O Livingston
    228 Livingston
  3. Alan N Houghton
    364 Houghton
Related MSK Work